- Sonic Healthcare maintains its FY EBITDA forecast in constant FX, expecting between A$1.87 billion and A$1.95 billion.
- The first half of FY26 is expected to account for approximately 45-46% of the full year’s forecast, aligning with historical patterns except for FY25, which was affected by unique, one-time factors.
- As of October 2025, statutory revenue growth stands at 17%, while constant currency revenue growth is at 12%, meeting Sonic’s expectations. Organic growth contributes 5% to this figure.
- The recent LADR acquisition and the HWE contract are contributing to revenue growth, albeit at lower margins.
- The forecast for depreciation expense, including leased assets, is projected between A$780 million to A$790 million in constant currency, representing a decreased percentage of revenue post-LADR acquisition and four months of trading.
- Interest expense increase in constant currency is now expected to be at the lower end of Sonic’s guidance range, between 15-20%.
- Current analyst recommendations for Sonic Healthcare include six buys, eight holds, and two sells.
Sonic Healthcare on Smartkarma
Analyst Coverage of Sonic Healthcare on Smartkarma
Analysts on Smartkarma, such as Baptista Research, have been closely following Sonic Healthcare. In their report titled “Sonic Healthcare: Initiation of Coverage- Inside the FY ‘26 Ramp-Up That Could Up Its Diagnostics Game!”, they highlighted Sonic Healthcare‘s latest half-year financial results up to December 31, 2024. The report noted the company’s strong rebound post-pandemic, showcasing significant improvement in key financial metrics driven by robust organic growth and cost control measures. With revenue reaching AUD 4.669 billion, reflecting an 8% increase from the previous period, Sonic Healthcare‘s recovery and growth trajectory have been commendable according to the analysts.
A look at Sonic Healthcare Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 4 | |
| Dividend | 4 | |
| Growth | 3 | |
| Resilience | 3 | |
| Momentum | 2 | |
| OVERALL SMART SCORE | 3.2 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on the Smartkarma Smart Scores, Sonic Healthcare Limited shows a positive long-term outlook. With a Value score of 4 and a Dividend score of 4, the company is perceived favorably in terms of its financial health and dividend-paying capacity. Although its Growth and Resilience scores sit at 3, indicating moderate performance in these areas, Sonic Healthcare is still positioned well for the future.
However, the company’s Momentum score of 2 suggests a slower pace in terms of market performance. Despite this, Sonic Healthcare continues to operate as a prominent player in the medical diagnostics sector, offering a wide range of services in Australia, New Zealand, and Europe. With a strong focus on pathology and diagnostic imaging services, it remains a key support system for medical practitioners and hospitals.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
